As a population that is particularly vulnerable to influenza infection and its complications this is a welcome decision, as it means the UK is the only European country where Trivalent Influenza Vaccine (TIV) High Dose is approved.
“We are pleased that a UK marketing authorisation has been granted for this vaccine. This approval is a positive step towards increasing the options available for healthcare professionals to help protect people 65 years of age and older against flu in the UK,” says Hugo Fry, managing director at Sanofi UK.
He continued, “Sanofi Pasteur is dedicated to supporting public health needs and continues to actively explore several innovative influenza vaccines for the future. We have worked closely with the UK regulator throughout this approval process and are grateful to them for their engaged and agile approach.”